As a central player of intratumoral hypoxia, HIF-1α has been associated with shorter time to biochemical recurrence, metastasis, and chemoresistance in PC patients, being an attractive target for cancer therapy (Vergis et al., 2008; Ranasinghe et al., 2013). The gene discussed is HIF1A; the disease is pachyonychia congenita.